FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to gynaecology, and can be used for treating osteopenic syndrome in postmenopausal obesity women. That is ensured by prescribing Estrogel - 17-β oestradiol gel 0.5 dose (1.25 g of gel) once a day in a continuous mode, Morozestan in dose of 100 mg intravaginally in a continuous mode combined with preparation Aquadetrim 2 drops day (1000 ME) for one year with subsequent control of bone metabolism and bone mineral density.
EFFECT: method enables reducing the frequency of osteopenia and stenoporosis, replenishing vitamin D deficiency with expressed protective effect on the entire skeleton.
1 cl, 5 tbl, 2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATMENT OF OSTEOPOROSIS IN WOMEN IN POSTMENOPAUSE AGAINST THE BACKGROUND OF OBESITY | 2017 |
|
RU2657789C1 |
| METHOD OF TREATING POSTMENOPAUSAL OSTEPOROSIS | 2009 |
|
RU2424815C2 |
| METHOD OF POSTMENOPAUSAL OSTEOPOROSIS THERAPY | 2009 |
|
RU2423982C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF MENOPAUSE OSTEOPOROSIS IN WOMEN | 2007 |
|
RU2379043C2 |
| METHOD OF PREDICTION OF ANNUAL ANTIOSTEOPOROTIC EFFICIENCY OF MENOPAUSAL HORMONAL THERAPY | 2015 |
|
RU2607304C1 |
| SYGETHIN-BASED PHARMACEUTICAL STRUCTURE FOR OSTEOPOROSIS PREVENTION AND TREATMENT (VERSIONS) | 2007 |
|
RU2356546C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH BREAST CANCER RECEIVING ANTIESTROGENIC THERAPY | 2020 |
|
RU2759233C1 |
| METHOD FOR DETERMINATION AND PREDICTION OF WOMAN'S HEALTH IN PERIMENOPAUSE AND POSTMENOPAUSE | 2016 |
|
RU2633926C1 |
| DIAGNOSTIC TECHNIQUE FOR OSTEOPOROSIS, METHOD FOR TESTING CAVITARY LESION CLOSURE BEHAVIOUR FOR ASSESSING EFFECTIVE USE OF VARIOUS OSTEOPROTECTORS | 2012 |
|
RU2511430C2 |
| METHOD OF REHABILITATION OF CHILDREN AND TEENAGERS WITH FRACTURES IN COMBINATION OF OSTEOPENIC SYNDROME | 2008 |
|
RU2391087C2 |
